1.
Touzeau C, Perrot A, Roussel M, Karlin L, Benboubker L, Jacquet C, Mohty M, Facon T, Manier S, Chretien M-L, Tiab M, Hulin C, Leleu X, Loiseau HA, Dejoie T, Planche L, Attal M, Moreau P. All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study. haematol [Internet]. 2022Jul.1 [cited 2024Dec.26];107(7):1693-7. Available from: https://haematologica.org/article/view/haematol.2021.280394